Abstract
Two hundred consecutive patients undergoing biliary-tract surgery were entered into a randomized trial of prophylactic single dose cephazolin or sulbactam/ampicillin. There was no overall difference in the infection rates between the two antibiotic groups, but in the group of patients with jaundice there was an excess of wound infections in the cephazolin group compared to the sulbactam/ampicillin group (35% vs. 14%). We conclude that sulbactam/ampicillin is a satisfactory prophylactic agent for use in biliary-tract surgical sepsis, and that it may be superior to cephazolin in jaundiced patients.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Ampicillin / administration & dosage
-
Ampicillin / therapeutic use*
-
Cefazolin / administration & dosage
-
Cefazolin / therapeutic use*
-
Cholecystectomy*
-
Humans
-
Injections, Intravenous
-
Jaundice / complications
-
Microbial Sensitivity Tests
-
Postoperative Complications / epidemiology
-
Postoperative Complications / etiology
-
Postoperative Complications / microbiology
-
Premedication*
-
Random Allocation
-
Sulbactam / administration & dosage
-
Sulbactam / therapeutic use*
-
Wound Infection / epidemiology
-
Wound Infection / etiology
-
Wound Infection / microbiology
Substances
-
Ampicillin
-
Cefazolin
-
Sulbactam